Article
Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors.
Nature communications - 24 Sept 2022
Kobayashi Yoshihisa, Oxnard Geoffrey R, Cohen Elizabeth F, Mahadevan Navin R, Alessi Joao V, Hung Yin P, Bertram Arrien A, Heppner David E, Ribeiro Mauricio F, Sacardo Karina P, Saddi Rodrigo, Macedo Mariana P, Blasco Rafael B, Li Jiaqi, Kurppa Kari J, Nguyen Tom, Voligny Emma, Ananda Guruprasad, Chiarle Roberto, Katz Artur, Tolstorukov Michael Y, Sholl Lynette M, Jänne Pasi A
Abstract excerpt
The clinical significance of gene fusions detected by DNA-based next generation sequencing remains unclear as resistance mechanisms to EGFR tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer. By studying EGFR inhibitor-resistant patients treated with a combination of an EGFR inhibitor and a drug targeting the putative resistance-causing fusion oncogene, we identify patients who benefit and those...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
